The Journal is Indexed in
4 - Comparison of chemotherapy protocols in NSCLC
Ö. Maral, D. Karaçetin, B. Yücel, Ö. Aksakal, D. Özcan, Y. Başer, O. İncekara
Objective: In spite of surgery, chemotherapy and radiotherapy, median survival in NSCLC is about 8 to 10 months. Thus alternative regimens are heeing tried. In this study we aimed to evaluated different chemotherapy regimens to their effectivies and tolerability.
Study design: The years of 1996-1999, 235 NSCLC patients who we are treated and followed up more than 6 months in Sisli Etfal Hospital, Radiation Oncology clinic are evaluated.
Results: The patients are compared, for the time to progression, Survival and side effects. 62 patients were received ICE, 67 patients were received cisplatinum and etoposide, 98 patients were received cisplatinum+vinorelbine+gemcitabine and 8 patients were received oral etoposide in 6 cycles. Chemotherapy was given after surgery and/or radiotheray. The time during the followed up métastasés were seen; 13 patients in ICE arm, 15 patients in cisplatinum+etoposide arm and. 21 patients in cisplatinum+vinorelbine+gemcitabine arm. Exitus was seen 41 patients in ICE arm, 36 patients in Cisplatinum+etoposide arm, 64 patients in cisplatinum+vinorelhine+gemcitabine arm and 4 patients in oral etoposide arm. The time to progression was 4.5 months in ICE arm, 4.1 months in cisplatinum+etoposide arm, 4 months in cisplatinum+vinorelbine+gemcitabine arm. Median survival was 11.1 months in ICE are, 12.2 months in cisplatinum+etoposide arm, 13.6 months in cisplatinum+vinorelbine+gemcitabine arm. (p: 0.11) There was not seen any toxicides WHO grade 3-4. There was no any patients who died during the chemotherapy arm, 36 patients in ci.splat.inum+etoposide arm, 64 patients in cisplatinum+vinorelbine+gemcitabine arm and 4 patients in oral etoposide. The time to progression was 4.5 months in ICE arm, 4.1 months in cisp- latinum+etoposide arm, 4 months in cisplatinum+vinorelbine+gemcitabine arm. Median survival was 11.1 months in ICE are, 12.2 months in cisplatinum+etoposide arm, 13.6 months in cisplatinum+vinorelbine+gemcitahine arm. (p: O.llJThere was not seen any toxicides WHO grade 3-4. There was no any patients who died during the chemotherapy.
Conclusion: Cisplatinum+vinorelbine+gemcitabine regimens is well tolerated. It has equavalent effectivines when compared the other standart regimens.
To read full article click